Tokyo Medical University Hospital - Dept of Neurology
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margania, Temur
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
Masuda, Masayuki
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
Utsugisawa, Kimiaki
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
Giorgadze, Gvantsa
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30

Download Options